A Phase Ib/II study of pembrolizumab, ibrutinib and rituximab in recurrent central nervous system lymphoma (CNSL)
Contact:
NCT Number:
Protocol:
AAAT7683
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses including other types of non-Hodgkin’s lymphoma.
Are you Eligible? (Inclusion Criteria)
- You are at least 18 years old on day of signing informed consent.
- You have recurrent primary central nervous system lymphoma (PCNSL).
Specialty Area(s)
Lymphoma
